ArticleBMC gastroenterology2026
Association between remnant cholesterol and cardiometabolic multimorbidity in non-alcoholic fatty liver disease patients: evidence from a cross-sectional study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardiometabolic multimorbidity (CMM) is a significant concern in patients with non-alcoholic fatty liver disease (NAFLD). However, the relationship between residual cholesterol (RC) levels and CMM risk in adult NAFLD patients remains poorly understood. This study aimed to investigate the association between RC levels and the risk of CMM in adult NAFLD patients using data from a large-scale, cross-sectional cohort.
methodsData were derived from the National Health and Nutrition Examination Survey (NHANES). Three multivariable logistic regression models and restricted cubic spline (RCS) analysis were employed to explore the relationship between RC and CMM risk in NAFLD patients, adjusting for potential confounders. Subgroup analyses and interaction tests were also conducted to assess the robustness of the findings.
resultsA significant positive association between RC levels and CMM risk was observed in NAFLD patients across all models (model1: OR = 1.094, 95% CI: 1.013,1.182, P = 0.023; model2: OR = 1.153, 95% CI: 1.061,1.253, P < 0.001; model3: OR = 1.158, 95% CI: 1.066,1.259, P < 0.001). Subgroup analysis showed that a stronger association between RC and CMM in patients with high fibrosis risk (P = 0.048). RCS analysis confirmed a nonlinear relationship, with CMM risk plateauing at higher RC concentrations.
conclusionsRC levels are significantly associated with CMM risk in adult NAFLD patients. These findings underscore the importance of monitoring RC levels as a potential marker for identifying individuals at higher risk of CMM, offering insights into the need for early intervention strategies. Further research is necessary to validate these findings and explore the association's underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.